Product Datasheet

PARG-IN-4

Catalog No. **BP-02061** · CAS **2988890-20-4** · Form **free base** · Physical state **solid** · Color **Light yellow to yellow** · Version **1.0** · Revision **2026-09-14**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Poly(ADP-ribose) Glycohydrolase (PARG); Apoptosis	**Cancer**

Molecular formula	$C_{20}H_{25}F_2N_7O_2S_2$
Molecular weight	**497.5850**

STRUCTURE



DESCRIPTION

PARG-IN-4 (Formula (A)) is an orally active and cell-permeable PARG inhibitor. PARG-IN-4 effectively inhibits tumor growth in mouse models. PARG-IN-4 can be used in cancer research.

BIOLOGICAL ACTIVITY

In Vitro

PARG-IN-4 (Formula (A)) affects the cell viability of SNU601 and RMUGS cells with EC50 of 11 nM and 4.2 nM, respectively; and exhibits antiproliferative activity against ovarian and breast cancer cells.

In Vivo

PARG-IN-4 (Formula (A)) (100 mg/kg; po; QD; 45 d) induces tumor regression in a patient-derived HBCx-34 xenograft mouse model.

SOLUBILITY

Soluble in DMSO : 20 mg/mL

REFERENCES

[1]. Paul A Barsanti, et al. Piperazine substituted indazole compounds as inhibitors of parg. Patent WO2023183850A1.